The First Dengue Vaccine in India Approved: QDENGA

News Desk, News Nation 360: Following the Drug Controller General of India's (DCGI) official market authorisation for QDENGA (TAK-003), Takeda Biopharmaceuticals India Pvt. Ltd. announced a historic public health milestone: QDENGA is the first dengue vaccine approved in India to prevent the disease in people aged 4 to 60. The groundbreaking vaccine eliminates the logistical obstacle of required pre-vaccination screening serotests and is designed as a live-attenuated tetravalent vaccine to protect against all four primary dengue virus serotypes. It can be administered subcutaneously regardless of an individual's history of dengue exposure. Operationalised under the direction of Dr Goh Choo Beng (Medical Affairs Head), Dr. Mahender Nayak (Head of Intercontinental Markets at Takeda), and Peter Streibl (General Manager for the Southeast Asia and India Cluster), the strategic rollout uses long-term, evidence-based preventive immunisation frameworks to directly address India's growing hyper-endemic burden. With a strong global footprint of over 32 million distributed doses, official World Health Organization (WHO) prequalification, and successful approval in 43 countries, QDENGA's clinical entry into the domestic market creates an essential healthcare mechanism to reduce disease transmission, lower dengue-related hospitalisation rates, and promote cross-sector collaborations to protect vulnerable populations nationwide.

Pic: Courtesy